CHICAGO – Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that China’s Patent Office has issued a Notice of Allowance to the University of Iowa Research...
PrecisionCHD™ is the First Integrated Epigenetic-Genetic-Based Blood Test for the Early Detection of Coronary Heart Disease CHICAGO – Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine...
PrecisionCHD is the only precision cardiovascular medicine test at the intersection of epigenetics, genetics, and artificial intelligence for the early detection of coronary heart disease. CHICAGO – Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial...
Leading Medical Practice in Idaho Will be the First Functional Medicine Clinic to Offer the Epi+Gen CHD Precision Cardiovascular Test CHICAGO – Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a leading precision cardiovascular diagnostics company, and Healing...
CHICAGO – Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a precision cardiovascular diagnostics company, announced today that it will attend the JP Morgan Healthcare Conference, January 9-12, 2023. The JP Morgan Healthcare Conference, which will be held in San...
Leading concierge medicine practice in Houston will be the first concierge medicine to offer the Epi+Gen CHD precision cardiovascular disease test to executives in Houston, Texas. HOUSTON – Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a leading precision...